DYAI dyadic.com: מקדם חוב לטווח ארוך להון

Dyadic International ensures stability through its C1 platform, which reduces production costs for B2B sector drugs. The current level of long-term financial dependence confirms the resilience of the model, where the 0.00 indicator determines the metric's magnitude. The business remains independent of economic cycles due to demand from pharma behemoths, while patent protection for fungal technologies creates a robust technological barrier.

Dyadic International (DYAI) operates in the high-risk biotechnology sector, where component procurement depends on global logistics. This indicator compares liabilities with maturities exceeding one year against equity to determine the level of financial autonomy. For an investor, this serves as a measure of resilience to geopolitical shocks and patent disputes. Reducing leverage minimizes default risks. The trend in the long-term debt-to-equity ratio allows for an assessment of the business's strategic margin of safety.